Home
>
US Stocks
>
G1 Therapeutics Inc

G1 Therapeutics Inc (GTHX)

$2.53

-0.01

(-0.39%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Insights on G1 Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 10.25M → 12.94M (in $), with an average increase of 20.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -33.64M → -32.53M (in $), with an average increase of 3.4% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 44.0% return, outperforming this stock by 88.2%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 21.0% return, outperforming this stock by 107.4%

Performance

  • $2.46
    $2.59
    $2.53
    downward going graph

    2.96%

    Downside

    Day's Volatility :5.03%

    Upside

    2.13%

    downward going graph
  • $2.38
    $17.49
    $2.53
    downward going graph

    5.93%

    Downside

    52 Weeks Volatility :86.39%

    Upside

    85.53%

    downward going graph

Returns

PeriodG1 Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-30.49%
0.7%
-7.0%
6 Months
-58.93%
-7.9%
-6.5%
1 Year
-44.15%
-2.0%
-6.8%
3 Years
-86.43%
25.4%
24.7%

Highlights

Market Capitalization
133.0M
Book Value
$0.87
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.68
PEG Ratio
0.0
Wall Street Target Price
11.17
Profit Margin
-219.66%
Operating Margin TTM
-200.79%
Return On Assets TTM
-37.86%
Return On Equity TTM
-173.6%
Revenue TTM
57.3M
Revenue Per Share TTM
1.25
Quarterly Revenue Growth YOY
87.6%
Gross Profit TTM
47.6M
EBITDA
-114.6M
Diluted Eps TTM
-2.68
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.52
EPS Estimate Next Year
-1.11
EPS Estimate Current Quarter
-0.64
EPS Estimate Next Quarter
-0.53

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for G1 Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 341.5%

Current $2.53
Target $11.17

Technicals Summary

Sell

Neutral

Buy

G1 Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
G1 Therapeutics Inc
G1 Therapeutics Inc
-14.81%
-58.93%
-44.15%
-86.43%
-93.54%
Moderna, Inc.
Moderna, Inc.
-2.19%
-29.52%
-8.32%
114.67%
590.97%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.43%
-4.6%
15.93%
18.38%
134.28%
Seagen, Inc.
Seagen, Inc.
-2.63%
59.03%
43.99%
21.05%
216.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.48%
0.7%
19.84%
13.84%
116.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
G1 Therapeutics Inc
G1 Therapeutics Inc
NA
NA
0.0
-1.52
-1.74
-0.38
0.0
0.87
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
G1 Therapeutics Inc
G1 Therapeutics Inc
Buy
$133.0M
-93.54%
NA
-219.66%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
590.97%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
134.28%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
216.49%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
116.25%
26.18
35.4%

Institutional Holdings

  • Fisher Asset Management, LLC

    5.27%

  • JPMorgan Chase & Co

    3.94%

  • Vanguard Group Inc

    3.85%

  • Millennium Management LLC

    3.24%

  • BlackRock Inc

    2.89%

  • Woodline Partners LP

    1.99%

Corporate Announcements

  • G1 Therapeutics Inc Earnings

    G1 Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.

Organization
G1 Therapeutics Inc
Employees
170
CEO
Mr. John E. Bailey Jr.
Industry
Health Technology

Discover More

FAQs